RetinalGenix Technologies Inc., a developmental-stage company specializing in ophthalmic screening and pharmacogenetic mapping, has entered into an agreement with LabCorp to support its DNA/RNA/GPS Pharmaco-Genetic Mapping platform. This collaboration aims to make genetic testing and high-resolution retinal imaging more accessible and cost-effective, reducing the need for expensive diagnostics like MRI and CT scans. The initiative is designed to allow early detection of eye and systemic diseases, enhancing diagnostic accuracy and broadening access to screening services. Patients will manage their appointments and test orders online, with results securely released after payment validation at LabCorp centers.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。